TCGA-E2-A15R-01A-11R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 58
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.290
- MYC_TARGETS_V2+0.290
- MITOTIC_SPINDLE+0.270
- G2M_CHECKPOINT+0.260
- HEDGEHOG_SIGNALING+0.260
- MYC_TARGETS_V1+0.260
- DNA_REPAIR+0.220
- OXIDATIVE_PHOSPHORYLATION+0.200
- PROTEIN_SECRETION+0.200
- HEME_METABOLISM+0.130
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.580
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.550
- IL6_JAK_STAT3_SIGNALING-0.530
- INFLAMMATORY_RESPONSE-0.500
- COAGULATION-0.460
- TNFA_SIGNALING_VIA_NFKB-0.460
- COMPLEMENT-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- IL2_STAT5_SIGNALING-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0HL-01A-11R-A10U-07 | — | B | 0.918 |
| 2 | SRR13780268 | — | cohortSC | 0.914 |
| 3 | MNG239 | — | — | 0.905 |
| 4 | TCGA-E2-A15S-01A-11R-A115-07 | — | B | 0.902 |
| 5 | BS_DFWFBYSN | medulloblastoma | — | 0.901 |
| 6 | BS_K74PZET7 | medulloblastoma | — | 0.899 |
| 7 | BS_Z7PKVY9J | medulloblastoma | — | 0.897 |
| 8 | MDT-AP-2917 | Med | Medulloblastoma | 0.897 |
| 9 | TCGA-56-7223-01A-11R-2045-07 | — | cohortMD1 | 0.894 |
| 10 | SRR5088887 | — | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.030 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |